Drug Profile
Renadirsen - Daiichi Sankyo
Alternative Names: DS-5141; DS-5141bLatest Information Update: 15 May 2023
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Inc
- Class Antisense oligonucleotides
- Mechanism of Action Dystrophin expression stimulants; Protein synthesis modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Duchenne muscular dystrophy
Most Recent Events
- 27 Apr 2023 Discontinued - Phase-II for Duchenne muscular dystrophy in Japan (SC)
- 15 Feb 2022 Phase II clinical development is ongoing for Duchenne muscular dystrophy in Japan
- 13 Jan 2021 Updated efficacy and adverse events data from a phase I/II trial in Duchenne muscular dystrophy released by Daichii Sankyo